Takeda forecasts $1.7B loss after Shire integration; Flagship’s preclinical biotech Axcella closes IPO with $71M+ haul

? Takeda’s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it’s giving analysts a negative surprise. Citing costs for integrating the Ireland-based Shire, the Japanese drugmaker forecasts an operating loss of $1.7 billion (193 billion yen) for the year through March 2019 — where analysts surveyed by Refinitiv estimated a profit of $2.08 billion (227.5 billion yen), according to Reuters. The predictions come as Takeda attempts to relieve its massive debt burden by divesting its non-core assets, including a dry eye drug and a

Click to view original post